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Introduction
Until recently, the occurrence of Hepatitis E in the western 
hemisphere did not amount to a clinical concern, due to its 
benign and usually sub-clinical evolution, as opposed to Asia 
and Africa, where large epidemies with high levels of lethality 
occur. More sensible diagnostic exams have shown a high 
prevalence of the infection through genotype 3 in the eastern 
hemisphere, with reports of hepatic infection, cirrhosis, and 
extremely severe systemic [1-3] and neurological extra-hepatic 
manifestations, especially on immunosuppressed patients [4-
6]. Hepatitis E: an emerging infection in developed countries 
[7], suggesting the occurrence of a new and important clinical 
and public health problem [3,8].
Chronic viral hepatitis E is the most prevalent worldwide. 
According WHO, HEV causes acute hepatic lesion annually 
in 3.5 million people, with around 70.000 deaths per year. It 
presents a single-stranded RNA genome, non-feces enveloped, 
but present on infected patients blood and in cell cultures. 
High genomic diversity with at least four major recognized 
genotypes (HEV1-4), and a few sub-genotypes, that can 
occur in humans with different epidemiologic and pathogenic 
characteristics. The molecular mechanisms of HEV replication 
are not fully understood.
The genotypes HEV 1 and HEV 2 occurs with high endemicity 
in Asia, Northern Africa, and Mexico. Feces-oral transmission, 
Anthroposis (man restricted). Endemic and/or epidemic in Asia 
(India: 2 million cases per year). 
The genotype HEV 3: Predominant in South and North 
America, Europe, and Southeast Asia. It infects animals 
(swine, poultry, rats, boar, rabbits and others) and humans. 
It can be transmitted through contaminated water, by meat 
consumption (<71 ºC), parenteral, blood, from mother to 
children, (perhaps sexually). Pigs have been reported to act 
as a reservoir for zoonotic viruses, sometimes emerging ones, 
and epidemiological studies have shown direct links between 
the consumption of uncooked pork offal and cases of hepatitis 
caused by the hepatitis E virus (HEV) genotype 3 in humans 
[9,10]. 
The genotype HEV 4 is predominant in Asia. Transmitted 
through water and contaminated food. Sporadic cases in both 
animals and humans.
HEV 5 only occurs in birds.
Family Hepeviridae. Gen. Orthohepevirus is a anthroposis (HEV 
1, HEV 2 – restricted to humans) and anthropozoonosis (HEV 3, 
HEV 4 – occurs in humans and animals: swine, poultry, boar, 
rabbits, rats, cattle, and others). The molecular mechanisms of 
HEV replication are not fully understood, mostly because there 
are no effi cient cell culture systems.
The incubation period is of 2 to 4 weeks. It can cause both 
acute and chronic cases. HEV infection may cause a wide range 
of clini cal presentations from subclinical or asympto matic 
forms to fulminant liver failure.
The diagnosis is made through serology, ELISA IgM/IgG 
(98% sensitivity / 75% in immunosuppressed) and molecular 
tests (RT-qPCR) and by validated exams, since the performance 
is variable.  Due to false negatives, it is needed to research 
through Western-blot and genome ORF3 detection techniques.
Objective
To discuss, considering recent fi ndings in the subject’s 
literature, the dimension of the problem and research if the 
Hepatitis E genotype 3, emergent and neglected in the western 
hemisphere, constitutes of new and important grievance to 
health. 
Metodology
Recent editions of several infectious disease books served 
as a basic substrate for the research. Then, the authors have 
investigated all relevant papers published in major 1990 
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databases to 2016, including:
• PUBMED - National Library of Medicine: http://www.
ncbi.nlm.nih.gov/pubmed
• Scielo: http://www.scielo.org
• LILACs: http://bibliomed.uol.com.br/LILACS/index.
cfm?libcatid=20025
• MEDLINE: http://medline.cos.com
• Google Academic: http://scholar.google.com.br
• OPAS / OMS: http://www.who.int
• CAPES: http://www.periodicos.capes.gov.br
• BIREME: http://bases.bireme.br/cgi-bin/wxislind.exe/
iah/online/
Results
Infection through genotype 3 is very little studied in 
industrialized Countries [3,7,11-13]. It can become chronic, 
aggravating immunosuppressed patients’ cases [14-22]. 
Several clinical situations of immunosuppression have 
been described in which the infection by HEV can produce 
extra-hepatic diseases and/or chronifi cation and worsening 
of liver disease, such as: HIV-Aids [23-26], organ or cell 
receptors [1,5,15,17,27,28], hematologic patients undergoing 
chemotherapy and immunotherapy [1,5], stem cells receptors, 
patients with schistosomiasis [29] and other immunologic 
diseases). 
In its chronic form, it can cause extra-hepatic disease: 
neurological [6,30-34], including cases of S. Guillain-
Barrè, neurologic pain amyotrophic, encephalitis, peripheral 
neuropathy, vestibular neuritis), confi rming that HEV in 
addition to hepatotropic is also neurotropic. 
There have been reports of cases with involvement of 
other organs in the HEV infection, such as: acute pancreatitis 
[35,36], immune-mediated diseases [37-40], (Hashimoto’s 
thyroiditis, glomerulonephritis, Henoch-Schonlein purpura, 
myasthenia gravis), hematologic diseases [38,41], (hemolytic 
anemia, acute myeloid leukemia, severe, thrombocytopenia), 
mixed cryoglobulinemia [42], infl ammatory bowel disease 
[43].  In pregnant women, infected during the fi rst trimester 
it generates a 15% to 25% lethality, in the Eastern hemisphere 
[44,45]. There are also registers of premature deliveries, with 
a child death rate under 30%. It is little studied in the western 
hemisphere. However, there are no reports of cases in the 
Western Region. 
Conclusion
1) Genotype 3 high seroprevalence in the western regions, 
the most pathogenic of all genotypes; 
2) The HEV virus can be transmitted via oral-oral route, 
parenteral via through blood contaminated, by animal 
meat and inter human transmission (including mother 
to child). Therefore, the risk of transmission through 
pork meat, and other animal products, implies the need 
of cook the meat for long periods at high temperatures 
(viruses can withstand temperatures of 71 °C for 5 
minutes) as boil the cow’s milk.
3) Extrahepatic neurologic manifestations are common 
in immunocompromised HEV infected patients, 
especially transplant recipients of solid organs or 
cells, in chemotherapy / corticoid therapy and AIDS 
with CD4 <250 cells / mm3. Several other extrahepatic 
impairments have been described in patients with HEV; 
4) HEV infection may accelerate the development of liver 
fi brosis in immunocompromised patients and other 
viral hepatitis or through other etiologies, causing 
cirrhosis in about 3 to 5 year; 
5) Reports suggest that it is a new and important clinical 
issue on the western hemisphere. Therefore, Hepatitis 
E is an emergent disease and effectively neglected in all 
its aspects in occidental regions. 
6) The exams (serological and molecular) are not available 
in most eastern countries, despite having many clinical 
indications. More sensible exams are needed.
7) It is always necessary to suspect of HEV in patients 
with elevated ALT without any apparent cause in the 
post-transplant; blood and plasma transfusion; and in 
hepatitis with fulminating or chronic evolution with 
fast evolution to cirrhosis.
8) The need for prophylactic ribavirin usage before 
immunosuppressive procedures is currently under 
discussion. 
9)  Its necessary to test the HEV 239 vaccine, human trials 
allowed in China (87% effi ciency with 3 dosages in 
genotypes 1 and 2) on Eastern hemisphere’s risk groups. 
Stimulate the pharmaceutical industry and researchers to 
develop new serological and molecular exams for more sensible 
and specifi c diagnosis.
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